{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:22:38Z","timestamp":1789014158153,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1053\/j.seminoncol.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T16:30:39Z","timestamp":1708619439000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists"],"prefix":"10.1053","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3979-9273","authenticated-orcid":false,"given":"Michael R.","family":"Bishop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2024.02.001_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2024.02.001_bib0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2024.02.001_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ymthe.2020.10.022","article-title":"Clinical perspective: treatment of aggressive B cell lymphomas with FDA-approved CAR-T cell therapies","volume":"29","author":"Leick","year":"2021","journal-title":"Mol Ther"},{"issue":"20","key":"10.1053\/j.seminoncol.2024.02.001_bib0005","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.3390\/cancers13205181","article-title":"Cellular therapy updates in B-cell lymphoma: the state of the CAR-T","volume":"13","author":"Crees","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2024.02.001_sbref0007","series-title":"(Axicabtagene ciloleucel) Prescribing information","year":"2022"},{"issue":"19","key":"10.1053\/j.seminoncol.2024.02.001_bib0008","first-page":"2307","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2024.02.001_sbref0009","series-title":"(Brexucabtagene autoleucel) Prescribing information","year":"2021"},{"key":"10.1053\/j.seminoncol.2024.02.001_sbref0010","series-title":"(Tisagenlecleucel) prescribing information","year":"2022"},{"key":"10.1053\/j.seminoncol.2024.02.001_sbref0011","series-title":"(Lisocabtagene maraleucel) prescribing information","year":"2022"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0012","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","volume":"59","author":"Roberts","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0013","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0014","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0015","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0016","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s11912-022-01330-z","article-title":"Supportive care for patients with lymphoma undergoing CAR-T-cell therapy: the advanced practice provider's perspective","volume":"24","author":"Granroth","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0017","first-page":"159","article-title":"Beyond CAR T-cell therapy: continued monitoring and management of complications","volume":"11","author":"Reiser","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0018","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0019","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0020","first-page":"1","article-title":"Revising the treatment pathways in lymphoma: new standards of care-how do we choose?","volume":"42","author":"Ngu","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0021","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0022","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0023","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0026","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2024.02.001_bib0027","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0028","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.clml.2018.07.203","article-title":"Axicabtagene ciloleucel in patients with refractory large B cell lymphoma: outcomes by prior lines of therapy in the pivotal phase 2 study, ZUMA-1","volume":"18","author":"Locke","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0029","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0030","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"suppl 15","key":"10.1053\/j.seminoncol.2024.02.001_bib0031","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2020.38.15_suppl.8039","article-title":"Real-world outcomes of elderly patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy","volume":"38","author":"Fitzgerald","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0032","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jval.2022.02.007","article-title":"Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-cell lymphoma","volume":"25","author":"Chen","year":"2022","journal-title":"Value Health"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0033","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1182\/blood-2022-155603","article-title":"Real-world impact of time from leukapheresis to infusion (vein-to-vein time) in patients with relapsed or refractory (r\/r) large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel","volume":"140","author":"Locke","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0034","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0036","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood-2022-169783","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0037","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0038","first-page":"1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2024.02.001_bib0039","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Non-relapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminoncol.2024.02.001_bib0040","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","article-title":"Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms","volume":"63","author":"Brudno","year":"2022","journal-title":"Leuk Lymphoma"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775424000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775424000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T09:06:24Z","timestamp":1722503184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775424000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0093775424000046"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2024.02.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}